Literature DB >> 18496427

Molecular implications of skin lesions in tuberous sclerosis.

Jarosław Jóźwiak1, Ryszard Galus.   

Abstract

Tuberous sclerosis (TS), neurocutaneous disorder resulting from the mutation of 1 of 2 genes, TSC1 or TSC2, is often associated with the formation of hamartomatous lesions in various organ systems, including the skin. TS patients may present with hypomelanic macules, confetti-like spots, facial angiofibromas, ungual fibromas, shagreen patches, forehead plaques, and other dermatological signs. Some of these manifestations are pathognomic for TS and thus should be carefully evaluated when TS diagnosis is suspected. Little is known however on molecular links connecting disease pathogenesis and formation of such hamartomas. In the current review, we describe molecular pathways thought to be responsible for the development of the disease and show how their upregulation may affect the skin. Special attention is paid to protein kinase B (PKB/Akt), extracellular signal-regulated kinase, and mammalian target of rapamycin, which have recently been found to participate in the control of melanin biosynthesis through microphthalmia-associated transcription factor and tyrosinase transcription.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18496427     DOI: 10.1097/DAD.0b013e31816e22a5

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

Review 1.  Perfect match: mTOR inhibitors and tuberous sclerosis complex.

Authors:  Cong Luo; Wen-Rui Ye; Wei Shi; Ping Yin; Chen Chen; Yun-Bo He; Min-Feng Chen; Xiong-Bin Zu; Yi Cai
Journal:  Orphanet J Rare Dis       Date:  2022-03-04       Impact factor: 4.123

2.  Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients.

Authors:  Mari Wataya-Kaneda; Mari Tanaka; Toshimitsu Hamasaki; Ichiro Katayama
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

3.  Clinical spectrum of MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities.

Authors:  Virginie Carmignac; Cyril Mignot; Emmanuelle Blanchard; Paul Kuentz; Marie-Hélène Aubriot-Lorton; Victoria E R Parker; Arthur Sorlin; Sylvie Fraitag; Jean-Benoît Courcet; Yannis Duffourd; Diana Rodriguez; Rachel G Knox; Satyamaanasa Polubothu; Anne Boland; Robert Olaso; Marc Delepine; Véronique Darmency; Melissa Riachi; Chloé Quelin; Paul Rollier; Louise Goujon; Sarah Grotto; Yline Capri; Marie-Line Jacquemont; Sylvie Odent; Daniel Amram; Martin Chevarin; Catherine Vincent-Delorme; Benoît Catteau; Laurent Guibaud; Alexis Arzimanoglou; Malika Keddar; Catherine Sarret; Patrick Callier; Didier Bessis; David Geneviève; Jean-François Deleuze; Christel Thauvin; Robert K Semple; Christophe Philippe; Jean-Baptiste Rivière; Veronica A Kinsler; Laurence Faivre; Pierre Vabres
Journal:  Genet Med       Date:  2021-04-08       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.